To review the diagnosis, prognosis, and treatment of patients with lower-risk myelodysplastic syndromes (LR-MDS), emphasizing the significance of structured assessments for improving patient outcomes.
Key Findings:
LR-MDS primarily affects the elderly, with a median age of onset above 70 years.
Anemia and complications from cytopenias can significantly impact quality of life and mortality.
Recent advancements in molecular characterization have improved understanding of MDS pathogenesis, highlighting the role of specific mutations.
Interpretation:
The integration of molecular diagnostics and structured assessments into clinical practice is essential for improving outcomes in LR-MDS patients.
Limitations:
Challenges remain in distinguishing LR-MDS from other conditions with overlapping features, such as aplastic anemia and other clonal hematopoiesis disorders.
Current diagnostic criteria may not capture all cases due to the complexity of clonal abnormalities.
Conclusion:
A comprehensive approach to diagnosis and treatment, incorporating new classifications and therapies, is vital for effectively managing patients with LR-MDS and improving clinical outcomes.
